Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7145978 | 0.88 | OPRM1 (0.50) | SIGMAR1KDM4EKMT2A | |
| SCHEMBL6876403 | 0.84 | SIGMAR1 (0.50) | SIGMAR1KDM4EKMT2A | |
| SCHEMBL6881131 | 0.80 | KDM4E (0.51) | KDM4EKMT2A | |
| SCHEMBL6874312 | 0.76 | SIGMAR1 (0.50) | SIGMAR1KMT2A | |
| SCHEMBL6880262 | 0.76 | SIGMAR1 (0.50) | SIGMAR1KMT2A | |
| SCHEMBL6875081 | 0.76 | SIGMAR1 (0.50) | SIGMAR1KMT2A | |
| Hydrochloric Acid SCHEMBL6884566 | 0.75 | SIGMAR1 (0.49) | SIGMAR1KMT2A | |
| SCHEMBL10521855 | 0.75 | SIGMAR1 (0.65) | SIGMAR1KDM4EKMT2A | |
| SCHEMBL7146364 | 0.74 | BCHE (0.37) | SIGMAR1KDM4E | |
| SCHEMBL28747604 | 0.73 | KDM4E (0.70) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278728-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001081303-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREAMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | disclosed |